Share on:

Blood and Marrow Transplant Fellowship (Minnesota)

Program Description

The one-year Blood and Marrow Transplant (BMT) Fellowship Program at Mayo Clinic offers you:

  • Preparation for a successful career in blood and marrow transplantation in a group practice or academic center
  • In-depth exposure to multidisciplinary approaches to hematological diseases from the blood and marrow transplantation perspective
  • Exciting research opportunities in the field of blood and marrow transplantation

As a Mayo Clinic blood and marrow transplant fellow, you will have access to clinical training in the inpatient and outpatient setting and exposure to a variety of hematological malignancies including lymphoma, multiple myeloma, leukemias, amyloidosis and myelodysplastic/myeloproliferative disorders. Many staff hematologists serve as faculty, and they offer a rich diversity of clinical expertise.

This fellowship includes laboratory experience in histocompatibility testing, cryopreservation, purging, stem cell harvesting, cell manipulation and dendritic cell therapy. Fellows train in inpatient and outpatient settings at Mayo Clinic's BMT unit. The BMT program is a part of Mayo Clinic's Transplant Center. Our facilities include a GMP-approved cell processing center and an NIH-sponsored Clinical Research Unit (CRU). Mayo Clinic's BMT unit is an approved ECOG Transplant Center. We perform a large number of blood, marrow and peripheral blood stem cell transplants, both autologous and allogeneic for hematological malignancies and solid tumors. Our center also performs non-myeloablative and haplo-identical stem cell transplantations.

Accreditation

Mayo's BMT Fellowship has been recognized as an approved transplant center within the Eastern Cooperative Oncology Group (ECOG) since 1988, and within the Children's Cancer Group (CCG) since 1990. In 1995, the National Marrow Donor Program (NMDP) accredited Mayo's BMT program to perform unrelated donor transplants. The program is currently undergoing voluntary certification by the Foundation for the Accreditation of Cellular Therapy (FACT).

Also see:

  • May 2, 2012
  • ART243264